Between Dec 19, 2024 and Jan 2, 2025, datasets can be submitted to DRUM but will not be processed until after the break. Staff will not be available to answer email during this period, and will not be able to provide DOIs until after Jan 2. If you are in need of a DOI during this period, consider Dryad or OpenICPSR. Submission responses to the UDC may also be delayed during this time.

Browsing by Subject "Division of Hematology, Oncology, and Transplantation"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Elucidating Genes that Promote the Development of Stem-Like Cells in Triple Negative Breast Cancers
    (2022) Makovec, Allison; Tape, Sydney; Richter, Camden; Rennhack, Jonathan P.; Hwang, Justin
  • Thumbnail Image
    Item
    Possibilities for Treatment of Melanoma: Effects on Cell Proliferation by Inhibition of Melanoma Chondroitin Sulfate Proteoglycan (MCSP) and B‐Raf In Vitro
    (2010-04-21) Cespedes Gomez, Omar
    The Map-Kinase cell signaling pathway controls cell growth by allowing cells to divide only in the presence of growth factor. Amplification of extracellular signaling proteins to downstream cytoplasmic signaling proteins B-RAF, Mek and Erk 1,2 leads to transcription of proteins involved in cell-cycle control. In 60% of Melanomas, B-RAF is found in a mutated form allowing division even in the absence of growth factors. Additionally, Melanoma Chondroitin Sulfate Proteoglycan is absent in normal melanocytes while frequently expressed in melanomas. MCSP sustains constitutive activation of Erk 1,2. Thus, it is of clinical significance to consider MCSP and B-RAF as cellular candidates for treatment of Melanoma due their modulation of Erk1, 2 activation. To determine cell proliferation effects by inhibition of MCSP and B-RAF, melanoma cell lines A375 and WM1341D were used. A375 contains MCSP and does not have mutant BRAF while WM1341D shows expression of MCSP and mutant B-RAF. Cells were treated with Raf kinase inhibitor Bay 43-9006 against B-RAF and MCSP antibody against MCSP. Simultaneous treatment had additive effects on A375 cell line while synchronous drug addition in WM1341D was not as effective as single administration of either MCSP antibody or Bay 43-9006. Thus, there was sensitization of A375 to Bay 43-9006 treatment by the addition of antibody while WM1341D cells showed resistance by the addition of antibody to Bay 43-9006.